Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 9/20 | 0.41 |
| ▸ | RARB | P10826 | 8/20 | 0.41 |
| ▸ | RARA | P10276 | 7/20 | 0.41 |
| ▸ | RXRA | P19793 | 14/20 | 0.40 |
| ▸ | RXRG | P48443 | 8/20 | 0.40 |
| ▸ | RXRB | P28702 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606906 | 1.00 | RARG (0.41) | RARGRARBRARARXRARXRG | |
| SCHEMBL3605961 | 0.87 | RXRA (0.40) | RARGRARBRARARXRARXRG | |
| SCHEMBL3605963 | 0.87 | RXRA (0.40) | RARGRARBRARARXRARXRG | |
| SCHEMBL2317337 | 0.87 | MEN1 (0.31) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2317332 | 0.87 | MEN1 (0.31) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3607935 | 0.86 | RXRA (0.43) | RARGRARBRARARXRARXRG | |
| SCHEMBL3607937 | 0.86 | RXRA (0.43) | RARGRARBRARARXRARXRG | |
| SCHEMBL3607891 | 0.86 | KDM4E (0.37) | ALDH1A1MAPTKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL3607886 | 0.86 | KDM4E (0.37) | ALDH1A1MAPTKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL3598469 | 0.85 | RXRA (0.39) | RARGRARBRARARXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| EP-1686983-B1 | USE OF PENTADIENOIC ACID DERIVATES FOR TREATEMENT OF HYPERURICEMIA | MERCK PATENT GMBH (DE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| EP-1535612-B1 | Treatment for hyperuricemia | MERCK SANTE SAS (FR) | 2006-09-13 | — | — | EP | disclosed |
| US-6596758-B1 | Treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds. | MERCK PATENT GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | XDH, URB2, ALOX12 | RARG 405/4885RARB 354/4885RARA 189/4885 |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | XDH, URB2, ALOX12 | RARG 405/4885RARB 354/4885RARA 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.